Paraneoplastic Disorders
Paraneoplastic Disorders
Paraneoplastic Neurological Syndromes are a set of degenerative autoimmune disorders due to the remote effects of cancer. Identification of a specific paraneoplastic antibody can guide the search for an underlying malignancy.
Myasthenia Gravis
Myastheni Gravis

Myasthenia Gravis Panel 2 with Reflex — Quantitative AChR binding, blocking, modulating antibodies with reflex to MuSK antibody testing.

Neuromyelitis Optica
Neuromyelitis Optica
When the syndrome is severe, and Multiple Sclerosis is ruled out, could it be Neuromyelitis Optica (NMO)?
Portrait of Dr. Ed Ginns

Edward I. Ginns, MD, Ph.D., DABCC, Medical Director

About the Doctor

Dr. Edward I. Ginns is Medical Director at Quest Diagnostics. Dr. Ginns is a leader in the field of lysosomal disorders at Quest.

Areas of Specialization

Dr. Ginns has published more than 130 articles and 10 book chapters in the fields of lysosomal and developmental disorders, neurogenetics, and molecular psychiatry. He has over two decades of translational research, diagnostic testing and team leadership experience in the academic and public sectors.
Professional Affiliations

Dr. Ginns has been affiliated with several medical and academic institutions and associations, including:

  • National Institute of Neurological Disorders and Stroke
  • National Institute of Mental Health
  • University of Massachusetts Medical School
  • American College of Neuropsychopharmacology
  • American Society of Human Genetics
  • American College of Medical Genetics
  • American Academy of Neurology
  • American Society of Biological Chemists
  • Society for Inherited Metabolic Disease
  • American Society of Gene and Cellular Therapy
  • Association for Molecular Pathology
  • American Association for Clinical Chemistry


Developmental and Metabolic Neurology
National Institute of Neurological Disorders & Stroke
Bethesda, Maryland

Department of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland

Albert Einstein College of Medicine
Bronx, New York


  • Doctor of Medicine
    Johns Hopkins University School of Medicine
    Baltimore, Maryland, USA
  • Ph.D. in Physical Chemistry
    Rensselaer Polytechnic Institute
    Troy, New York, USA
    Board Certifications

American Board of Psychiatry and Neurology

American Board of Clinical Chemistry

Select Publications

Disruption of Sonic Hedgehog Signaling in Ellis van-Creveld Dwarfism Confers Protection Against Bipolar Disorder. Nature Molecular Psychiatry. 2014.

Dr. Nigel Clarke

Nigel Clarke, PhD, Vice President, Special Technology, San Juan Capistrano, California

Dr. Clarke received his Ph.D. in Mass Spectrometry and Analytical Chemistry from the University of Kent at Canterbury in England, and completed postdoctoral fellowship training in Biomedical Mass Spectrometry at the Mayo Clinic in Rochester, MN. He was a Principle Investigator at the Schering-Plough Research Institute in Kenilworth, NJ where he ran the drug discovery metabolite identification group and worked at ActivX Biosciences (a biotechnology company) as Director of Mass Spectrometry before joining Quest Diagnostics Nichols Institute.

At Nichols Institute, Dr. Clarke is the Vice President for Advance Technology overseeing R&D groups which develop the LC-MS/MS and Immunology assays utilized across Quest Diagnostics. His staff is involved in training visiting scientists from other Quest Diagnostics business units, adopting the new technology and assays developed in Dr. Clarke’s laboratory. He also oversees the running of LCMS assays across multiple operations laboratories within the Quest network.

Dr Clarke is involved in several academic collaborations with groups at multiple sites including Cedars-Sinai, the CDC and Massachusetts General Hospital and UCSF, utilizing the LC-MS/MS assays he and his group has developed to create and refine standardized reference ranges for both clinical studies and diagnostic usage.

He has published widely on his use of mass spectrometry in a variety of biological arenas, is a reviewer for multiple journals and received multiple awards including the Michael Barber Award for Mass Spectrometry, The President’s Award for Discovery from the Schering-Plough Research Institute and the Medical Innovations Award from Quest Diagnostics.

Dr. Anthony Horner

Anthony Horner, MD, Associate Medical Director, Immunology

Dr. Horner is a board certified pediatrician with subspecialty certification in allergy and immunology. He received his bachelor's degree from the University of California, San Diego in biochemistry and cell biology. He received his M.D. from Saint Louis University and trained in pediatrics at the University of California, Los Angeles. He completed fellowship in allergy and immunology at Boston Children’s Hospital, Harvard Medical School. After his fellowship, Dr. Horner joined the medical school faculty at the University of California, San Diego within the Division of Allergy, Immunology, and Rheumatology, where he held joint appointments in the departments of medicine and pediatrics. Over the next 20 years, his laboratory was funded by the NIH/NIAID and he conducted basic and translational research that focused initially on toll-like receptors and subsequently on the role of the environment in the pathogenesis of allergic diseases. Dr. Horner has served on NIH and foundation grant review study sections, and the editorial review board of several journals, including the Journal of Allergy and Clinical Immunology. He is the author of more than 70 peer-reviewed papers, book chapters, and reviews and Dr. Horner continues to serve on several national professional society committees.

Understanding Paraneoplastic Syndromes

A video with Dr. Stanly Naides